Weight benefit
Studies in patients with type 2 diabetes treated with basal insulin in combination with oral antidiabetic drugs demonstrated that glycaemic control (HbA1c) with Levemir® is comparable to NPH insulin and insulin glargine and associated with less weight gain, please see the table below.1
• Levemir® reduces weight gain without compromising HbA1c control4
• 13 out of 13 randomised clinical trials showed significantly less weight gain with the use of Levemir® compared to NPH4,9-20
• In the PREDICTIVE™ study (an observational study that reflects daily clinical practice), the weight benefit of Levemir® increased with baseline BMI in insulin naïve type 2 patients initiated on Levemir® (±orals)5
